{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:36:26Z","timestamp":1779906986365,"version":"3.53.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.semarthrit.2015.06.007","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T21:21:29Z","timestamp":1434662489000},"page":"321-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Advances in the treatment of ocular dryness associated with Sj\u00f6gren\u05f3s syndrome"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8911-4113","authenticated-orcid":false,"given":"Coziana","family":"Ciurtin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Ostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viorica M.","family":"Cojocaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2015.06.007_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jaut.2013.02.001","article-title":"Sjogren\u05f3s syndrome and the epithelial target: a comprehensive review","volume":"42","author":"Barrera","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/MNM.0b013e328339bdf6","article-title":"Quantitative and visual evaluation of salivary and thyroid glands in patients with primary Sjogren\u05f3s syndrome using salivary gland scintigraphy: relationship with clinicopathological features of salivary, lacrimal and thyroid glands","volume":"31","author":"Gune","year":"2010","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/ard.2007.073650","article-title":"Prevalence of Sjogren syndrome among Nagasaki atomic bomb survivors","volume":"67","author":"Hida","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3109\/14397595.2013.843765","article-title":"Primary and secondary surveys on epidemiology of Sjogren\u05f3s syndrome in Japan","volume":"24","author":"Tsuboi","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib5","article-title":"Epidemiology of primary Sjogren\u05f3s syndrome: a systematic review and meta-analysis","author":"Qin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaut.2009.09.009","article-title":"Sjogren syndrome: advances in the pathogenesis from animal models","volume":"33","author":"Chiorini","year":"2009","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00002281-200309000-00007","article-title":"New concepts in the pathogenesis of Sjogren syndrome: many questions, fewer answers","volume":"15","author":"Hansen","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib8","doi-asserted-by":"crossref","first-page":"160491","DOI":"10.1155\/2013\/160491","article-title":"The immune factors involved in the pathogenesis, diagnosis, and treatment of Sjogren\u05f3s syndrome","volume":"2013","author":"Huang","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cyto.2014.02.009","article-title":"Early events in Sjogren\u05f3s syndrome pathogenesis: the importance of innate immunity in disease initiation","volume":"67","author":"Kramer","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/acr.21887","article-title":"Risk of non-Hodgkin\u05f3s lymphoma in primary Sjogren\u05f3s syndrome: a population-based study","volume":"65","author":"Johnsen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ophtha.2010.12.016","article-title":"Treatment of Sjogren\u05f3s syndrome-associated dry eye an evidence-based review","volume":"118","author":"Akpek","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib13","first-page":"240","article-title":"Dry eye: an inflammatory ocular disease","volume":"9","author":"Hessen","year":"2014","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11882-005-0077-x","article-title":"Recent advances in the management of ocular complications of Sjogren\u05f3s syndrome","volume":"5","author":"Samarkos","year":"2005","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib15","first-page":"2351","article-title":"Psychological and somatic predictors of perceived and measured ocular dryness of patients with primary Sjogren\u05f3s syndrome","volume":"32","author":"Vriezekolk","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archopht.122.3.369","article-title":"Incidence of dry eye in an older population","volume":"122","author":"Moss","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib17","doi-asserted-by":"crossref","first-page":"e78657","DOI":"10.1371\/journal.pone.0078657","article-title":"Incidence and pattern of dry eye after cataract surgery","volume":"8","author":"Kasetsuwan","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1756-185X.2012.01717.x","article-title":"A study of the prevalence of sicca symptoms and secondary Sjogren\u05f3s syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile","volume":"15","author":"Haga","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib19","first-page":"243","article-title":"Epidemiology of ocular involvement in autoimmune diseases","volume":"46","author":"Ciurtin","year":"2008","journal-title":"Rom J Intern Med"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00003226-200003000-00005","article-title":"Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis","volume":"19","author":"Avisar","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.eye.6701537","article-title":"Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjogren\u05f3s syndrome patients","volume":"19","author":"Aragona","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/jop.2006.0091","article-title":"Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren\u05f3s syndrome","volume":"23","author":"Hong","year":"2007","journal-title":"J Ocul Pharma"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib23","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1167\/iovs.13-11798","article-title":"A study of the short-term effect of artificial tears on contrast sensitivity in patients with Sjogren\u05f3s syndrome","volume":"54","author":"Zhang","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib24","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00296-013-2769-1","article-title":"Punctal plugs versus artificial tears for treating primary Sjogren\u05f3s syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function","volume":"33","author":"Qiu","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib25","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/bjo.86.8.879","article-title":"Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren\u05f3s syndrome patients","volume":"86","author":"Aragona","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/bjo.83.4.390","article-title":"Treatment of dry eye by autologous serum application in Sjogren\u05f3s syndrome","volume":"83","author":"Tsubota","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/02713683.2012.720340","article-title":"Comparison of autologous serum eye drops with different diluents","volume":"38","author":"Cho","year":"2013","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/ICO.0b013e318074e460","article-title":"Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye","volume":"26","author":"Roberts","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib29","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","article-title":"Evaluation of topical cyclosporine for the treatment of dry eye disease","volume":"126","author":"Perry","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/ICO.0b013e3181a16472","article-title":"High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimen","volume":"28","author":"Dastjerdi","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2008.08.015","article-title":"A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome","volume":"147","author":"Kim","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib33","first-page":"712","article-title":"The mode of action of pilocarpine on outflow resistance in the eye of a primate (Cercopithecus ethiops)","volume":"1","author":"Barany","year":"1962","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib34","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren\u05f3s syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.rhu.0000135553.08057.21","article-title":"Successful treatment of dry mouth and dry eye symptoms in Sjogren\u05f3s Syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study","volume":"10","author":"Papas","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","article-title":"Therapeutic effect of cevimeline on dry eye in patients with Sjogren\u05f3s syndrome: a randomized, double-blind clinical study","volume":"138","author":"Ono","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib38","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren\u05f3s syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib39","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/rheumatology\/kep104","article-title":"Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren\u05f3s syndrome","volume":"48","author":"Rihl","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib40","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00296-010-1415-4","article-title":"Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren\u05f3s syndrome","volume":"31","author":"Yavuz","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib42","first-page":"555","article-title":"Methotrexate in primary Sjogren\u05f3s syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib43","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sjogren\u05f3s syndrome: a phase II pilot study","volume":"66","author":"van Woerkom","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib44","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren\u05f3s syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15027732.1986.12461421","article-title":"Cyclosporin a therapy in patients with primary Sjogren\u05f3s syndrome: results at one year","volume":"61","author":"Drosos","year":"1986","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib46","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/art.20416","article-title":"Prominent adverse effects of thalidomide in primary Sjogren\u05f3s syndrome","volume":"51","author":"Pillemer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","article-title":"Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model","volume":"23","author":"Urashima","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib48","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib49","first-page":"2721","article-title":"Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjogren\u05f3s syndrome: a randomized, double-blind, placebo-controlled clinical trial","volume":"127","author":"Hu","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bjo.2010.193029","article-title":"Long-term outcomes of MICOF keratoprosthesis in the end stage of autoimmune dry eyes: an experience in China","volume":"96","author":"Huang","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib51","first-page":"2566","article-title":"Quadricepital tendon enthesitis in psoriatic arthritis and rheumatoid arthritis: ultrasound examinations and clinical correlations","volume":"28","author":"Frediani","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib52","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sjogren\u05f3s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib53","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib54","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sjogren\u05f3s syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib56","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sjogren\u05f3s syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib57","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren\u05f3s syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib58","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren\u05f3s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib59","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.20789","article-title":"Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjogren\u05f3s syndrome","volume":"52","author":"Ping","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2015.06.007_bib60","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1185\/030079906X132640","article-title":"Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion","volume":"22","author":"Asbell","year":"2006","journal-title":"Curr Med Res Opin"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215001456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017215001456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:49:41Z","timestamp":1748458181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017215001456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0049017215001456"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.007","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the treatment of ocular dryness associated with Sj\u00f6gren\u05f3s syndrome","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}